Study guide
3.3 Direct & Indirect Immunofluorescence Microscopy
UEMS European Board of Dermatovenereology Diploma Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Eligibility & Examination Regulations
1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition
2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology
2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns
3 Chapter 3: Dermatopathology & Diagnostic Procedures
3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy
4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology
4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance
5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease
5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
6 Chapter 6: Hair, Nails & Pigmentary Disorders
6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation
7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses
8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease
8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease
9 Chapter 9: Autoimmune Bullous Diseases
9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
10 Chapter 10: Eczematous Disorders, Urticaria & Allergology
10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis
11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
12 Chapter 12: Paediatric & Genetic Dermatology
12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa
13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections
13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections
14 Chapter 14: Viral & Fungal Cutaneous Infections
14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses
15 Chapter 15: Sexually Transmitted Infections & Genital Infections
15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours
17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases
18 Chapter 18: Melanocytic Naevi & Melanoma
18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma
19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas
19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas
20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing
20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures
21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy
22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision
22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review
3.3 Direct & Indirect Immunofluorescence Microscopy
Key Takeaways Explain This Topic AI
For autoimmune bullous disease diagnosis, direct immunofluorescence (DIF) requires a punch biopsy of perilesional, intact, normal-appearing skin or mucosa (within 1–2 cm of an active blister); biopsying the blister roof or ulcer bed is a catastrophic error yielding false-negative results due to immunoreactant degradation.
Specimens for DIF must be transported in Michel's or Zeus transport medium at room temperature or snap-frozen in liquid nitrogen with OCT; formalin fixation must never be used because it permanently cross-links epitopes and generates blinding background autofluorescence.
Intercellular IgG and C3 deposition in a 'fish-net' or 'chicken-wire' pattern across the epidermis is diagnostic of pemphigus, whereas continuous linear IgG and C3 along the dermo-epidermal basement membrane zone characterizes the pemphigoid group.
Salt-split skin indirect immunofluorescence (IIF) differentiates bullous pemphigoid (epidermal roof pattern targeting BP180 NC16A and BP230) from epidermolysis bullosa acquisita and anti-laminin-332 mucous membrane pemphigoid (dermal floor pattern targeting type VII collagen and laminin-332, respectively).
The Lupus Band Test requires granular deposition of IgM, IgG, or C3 along the dermo-epidermal junction; a positive band in non-lesional, sun-protected skin is highly specific for systemic lupus erythematosus (SLE) and correlates strongly with active lupus nephritis.
Last updated: September 2026
3.3 Direct & Indirect Immunofluorescence Microscopy
Quick Summary: Immunofluorescence microscopy is the gold standard for diagnosing autoimmune bullous disorders and cutaneous lupus erythematosus. Direct immunofluorescence (DIF) detects in vivo tissue-bound antibodies and complement using monospecific fluorophore-conjugated antisera on perilesional cryosections. Indirect immunofluorescence (IIF) on 1.0 M salt-split human skin separates the lamina lucida, allowing differentiation between epidermal roof-binding disorders ( bullous pemphigoid ) and dermal floor-binding disorders ( epidermolysis bullosa acquisita , anti-laminin-332 pemphigoid ).
Principles & Methodology of Direct Immunofluorescence (DIF)
Direct immunofluorescence visualizes patient-derived autoantibodies and complement components deposited in vivo within cutaneous or mucosal tissues. Fresh cryostat sections (4–6 μ m \mu m μ m ) are incubated with monospecific fluorescein isothiocyanate (FITC)-conjugated antibodies targeting human IgG , IgA , IgM , complement C3 , and fibrinogen .
1. Biopsy Site Selection Protocols
Selecting the precise anatomical site for biopsy is critical for obtaining diagnostic immunofluorescence:
Autoimmune Bullous Diseases (Pemphigus, Pemphigoid, EBA):
Must biopsy perilesional, clinically normal-appearing skin or mucosa , ideally within 1 to 2 cm of an active, intact blister.
Pitfall: Biopsying the blister center, blister roof, or an eroded ulcer base leads to false-negative results. Detached epidermis undergoes secondary necrosis, inflammatory proteases digest immunoglobulin and complement epitopes, and re-epithelialization displaces immune deposits.
Dermatitis Herpetiformis (DH):
Must biopsy normal-appearing, non-lesional perilesional skin (commonly buttock, extensor forearm, or lumbar back).
Pitfall: Biopsying an active erythematous papule or microvesicle yields false-negative DIF because dense neutrophilic microabscesses at the dermal papillae tips release proteases that rapidly degrade the diagnostic granular IgA deposits.
Cutaneous Vasculitis:
Biopsy an early, fresh purpuric lesion (less than 24 to 48 hours old) . Biopsies performed after 48 hours frequently show false-negative results because infiltrating neutrophils destroy immune complexes.
Lupus Band Test (LBT):
Lesional Skin Biopsy: Confirms cutaneous lupus erythematosus (positive in ~70–90% of discoid lupus and SLE lesions).
Non-lesional, Sun-Exposed Skin (e.g., extensor forearm): Positive in ~70% of active SLE patients, negative in discoid lupus.
Non-lesional, Sun-Protected Skin (e.g., inner medial upper arm, buttock): Positive in ~50–60% of SLE patients; highly specific for systemic lupus erythematosus (SLE) and correlates with high titers of anti-dsDNA antibodies, hypocomplementemia, and active proliferative lupus nephritis.
2. Specimen Handling & Transport Media
Michel's Transport Medium: A buffered ammonium sulfate solution (pH 7.0–7.2) containing potassium citrate and N-ethylmaleimide. It stabilizes immune deposits without cross-linking tissue proteins, preserving antigenicity for up to 14 days at room temperature .
Zeus Medium: An alternative buffered salt solution with comparable efficacy.
Snap-Freezing: Tissue embedded in OCT compound and frozen immediately in liquid nitrogen (−196°C) or on dry ice.
Formalin Prohibition: Formaldehyde fixation induces methylene bridge formation between amino acid side chains, permanently altering antigenic epitopes and generating blinding green autofluorescence. A formalin-immersed specimen cannot be rescued for DIF.
Diagnostic Direct Immunofluorescence (DIF) Patterns Cutaneous Immunofluorescence Patterns:
- ├── Intercellular Epidermal ("Fish-Net / Chicken-Wire")
- │ ├── IgG + C3 throughout all strata → Pemphigus vulgaris (Dsg3 ± Dsg1)
- │ └── IgG + C3 in upper strata / subcorneal → Pemphigus foliaceus (Dsg1)
- ├── Continuous Linear Basement Membrane Zone (BMZ)
- │ ├── Linear C3 (± IgG) along lamina lucida → Bullous pemphigoid
- │ ├── Linear IgG / IgA / C3 along BMZ → Mucous membrane pemphigoid
- │ ├── Broad, intense linear IgG + C3 (sub-lamina densa) → Epidermolysis bullosa acquisita
- │ └── Continuous linear IgA along BMZ → Linear IgA bullous dermatosis
- ├── Granular Dermal Papillary Tips
- │ └── Granular / fibrillar IgA at papillary apices → Dermatitis herpetiformis (eTG / TG3)
- └── Granular Dermo-Epidermal Junction (DEJ) Band
- └── Continuous granular band of IgM, IgG, and C3 → Lupus Band Test (SLE / CLE)
- Detailed Pattern Descriptions
- 1. Intercellular Epidermal Pattern ("Fish-net" / "Chicken-wire")
Pemphigus Vulgaris: IgG (predominantly IgG4 and IgG1) and complement C3 deposited along the cell surface membranes of keratinocytes throughout the entire thickness of the epidermis and mucosal epithelium. Autoantibodies target desmoglein 3 (mucosal-dominant) or desmoglein 3 and 1 (mucocutaneous).
Pemphigus Foliaceus: Intercellular IgG and C3 deposition concentrated predominantly in the upper spinous, granular, and subcorneal layers, sparing the lower epidermis. Autoantibodies target desmoglein 1 .
Paraneoplastic Pemphigus (PNP): Intercellular IgG and C3 throughout the epidermis accompanied by concomitant continuous linear or granular basement membrane zone deposition . Autoantibodies recognize plakin family proteins (envoplakin, periplakin, desmoplakin I/II, plectin) and alpha-2-macroglobulin-like-1 (A2ML1).
2. Continuous Linear Basement Membrane Zone Pattern
Bullous Pemphigoid (BP): Bright, continuous, linear deposition of C3 (found in >95% of cases; often stronger than IgG) and IgG (predominantly IgG4) along the dermo-epidermal junction in a ribbon-like distribution.
Mucous Membrane Pemphigoid (MMP): Continuous linear deposition of IgG, IgA, and/or C3 along the BMZ of oral, conjunctival, or genital mucosa. Linear IgA is prominent in ocular cicatricial pemphigoid.
Epidermolysis Bullosa Acquisita (EBA): Dense, continuous, broad linear band of IgG and C3 localized to the anchoring fibril zone (sub-lamina densa). Autoantibodies target type VII collagen .
Linear IgA Bullous Dermatosis (LABD): Homogeneous, continuous linear band of IgA along the BMZ. Target autoantigen is typically the 97-kDa (LAD-1) or 120-kDa shed ectodomain of BP180. Most common drug trigger is vancomycin .
3. Granular Dermal Papillary Pattern
Dermatitis Herpetiformis (Duhring's Disease): Granular, clumped, or fibrillar deposits of IgA exclusively clustered at the apices (tips) of dermal papillae , occasionally merging into a continuous granular band along the dermal-epidermal junction. Target autoantigen is epidermal transglutaminase (eTG / TG3) . Accompanied by gluten-sensitive enteropathy (celiac disease).
4. Granular Dermo-Epidermal Junction Pattern (Lupus Band Test)
Continuous or coarse granular band of IgM, IgG, and/or C3 aligned along the dermo-epidermal junction. IgM is the most frequently detected immunoreactant, but IgG is more specific for systemic disease.
Salt-Split Skin Indirect Immunofluorescence (IIF)
Indirect immunofluorescence (IIF) evaluates circulating serum autoantibodies against skin antigens using epithelial substrates (monkey esophagus, normal human skin). However, routine IIF cannot differentiate between antibodies targeting hemidesmosomal antigens (bullous pemphigoid) and those targeting anchoring fibrils (epidermolysis bullosa acquisita) because both produce identical linear BMZ patterns.
The Salt-Split Skin Technique
Method: Normal human skin is incubated in 1.0 M sodium chloride (NaCl) at 4°C for 48–72 hours. This hypertonic incubation cleanly cleaves the dermo-epidermal junction through the lamina lucida , separating the epidermis (roof) from the dermis (floor).
Patient serum is applied to the split substrate, followed by FITC-conjugated anti-human IgG. Salt-Split Skin Separation (1.0 M NaCl):
- =======================================================
- EPIDERMAL ROOF (Hemidesmosomes / Upper Lamina Lucida)
- BP180 (Type XVII Collagen, NC16A domain)
- BP230 (Dystonin / Bullous Pemphigoid Antigen 1)
- Alpha-6-beta-4 Integrin (some MMP subtypes)
- ---------------- CLEAVAGE PLANE (Lamina Lucida) -------
- DERMAL FLOOR (Lamina Densa / Sub-Lamina Densa)
- Type VII Collagen (Anchoring Fibrils) → EBA
- Laminin-332 (Epiligrin) → Anti-Laminin-332 MMP
- Laminin gamma-1 (p200 antigen) → Anti-p200 Pemphigoid
- =======================================================
- Clinical and Oncological Implications
Epidermal Roof Binding Pattern:
Bullous Pemphigoid: Serum autoantibodies bind the epidermal roof, reacting against BP180 (NC16A domain) and BP230 .
Pemphigoid Gestationis: Strongly roof-binding; serum contains IgG 'HG factor' that avidly fixes C3 to the roof.
Dermal Floor Binding Pattern:
Epidermolysis Bullosa Acquisita (EBA): Serum autoantibodies bind the dermal floor, recognizing the non-collagenous NC1 and NC2 domains of type VII collagen within anchoring fibrils.
Anti-Laminin-332 Mucous Membrane Pemphigoid (Anti-Epiligrin Pemphigoid): Autoantibodies bind the dermal floor, targeting laminin-332 . High-yield exam fact: Approximately 25% to 30% of patients with anti-laminin-332 MMP harbor an occult internal malignancy , most commonly adenocarcinoma of the gastrointestinal tract, lung, or genitourinary system. Age-appropriate malignancy screening is recommended at diagnosis.
Anti-p200 / Anti-Laminin γ 1 \gamma 1 γ 1 Pemphigoid: Serum autoantibodies bind the dermal floor, recognizing the 200-kDa glycoprotein laminin γ 1 \gamma 1 γ 1 . Clinically mimics bullous pemphigoid or linear IgA disease and is frequently associated with pre-existing psoriasis vulgaris .
Loading diagram... Subepidermal Blistering Autoimmune Disease Algorithm
Comparative Immunofluorescence Profiles in Autoimmune Bullous & Connective Tissue Diseases
Disease Primary Autoantigens Direct Immunofluorescence (DIF) Pattern Salt-Split Skin IIF Pattern Diagnostic Pearls & Clinical Associations
Pemphigus Vulgaris Desmoglein 3 (mucosal); Desmoglein 3 and 1 (mucocutaneous) Intercellular "fish-net" IgG and C3 throughout full epidermal thickness Not applicable (intraepidermal target) Flaccid bullae, suprabasal tombstoning, positive Nikolsky sign, prominent mucosal ulcerations
Pemphigus Foliaceus Desmoglein 1 Intercellular "fish-net" IgG and C3 restricted to upper spinous/granular layers Not applicable (intraepidermal target) Superficial crusted plaques, subcorneal blister, intact mucosal surfaces spared
Paraneoplastic Pemphigus Plakins (envoplakin, periplakin, desmoplakins), A2ML1, Dsg3/1 Intercellular IgG/C3 plus linear/granular BMZ deposition Stains rat bladder epithelium (simple/transitional epithelium) Severe intractable stomatitis, lichenoid/erythema multiforme-like rash, occult hematologic neoplasm (CLL, Castleman)
Bullous Pemphigoid BP180 (type XVII collagen, NC16A domain), BP230 Continuous linear C3 (>95%) and IgG along dermo-epidermal junction Epidermal Roof pattern Tense bullae, urticarial prodrome, elderly onset, subepidermal split with eosinophils
Pemphigoid Gestationis BP180 (NC16A domain) Continuous linear C3 (100%) ± \pm ± faint linear IgG along BMZ Epidermal Roof pattern (C3-fixing IgG) 2nd/3rd trimester pregnancy or postpartum, periumbilical urticarial plaques transforming into tense bullae
Mucous Membrane Pemphigoid BP180 (C-terminal/NC16A), laminin-332, α 6 β 4 \alpha 6 \beta 4 α 6 β 4 integrin Continuous linear IgG, IgA, or C3 along mucosal/cutaneous BMZ Variable: Roof (BP180) vs. Floor (laminin-332) Scarring mucosal erosions (oral, conjunctival symblepharon, laryngeal stenosis, esophageal strictures)
Epidermolysis Bullosa Acquisita Type VII collagen (NC1/NC2 domains in anchoring fibrils) Thick, intense linear IgG and C3 along BMZ (sub-lamina densa) Dermal Floor pattern Mechanobullous fragility, milia formation, scarring over trauma-prone extensor surfaces, resistant to therapy
Linear IgA Bullous Dermatosis 97-kDa / 120-kDa fragment of BP180 (LAD-1) Exclusive continuous linear IgA along BMZ Mostly Roof pattern (rare floor subtypes) "Crown of jewels" or "string of pearls" arranged vesicles, vancomycin exposure, pediatric variant (CBDC)
Dermatitis Herpetiformis Epidermal transglutaminase (eTG / TG3) Granular / clumped IgA deposits clustered at dermal papillae tips Negative on salt-split skin (serum anti-tTG/eTG IgA positive on ELISA) Extremely pruritic vesicles on elbows, knees, buttocks; celiac disease enteropathy; responds rapidly to dapsone
Systemic Lupus Erythematosus (LBT) Multiple (DNA, histones, ribonucleoproteins) Continuous granular IgM, IgG, and C3 along dermo-epidermal junction Not applicable Positive in non-lesional, sun-protected skin; strongly correlates with active lupus nephritis and systemic flares